Stocktoria
Summit Therapeutics Inc. SMMT
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2004-10-14
Summit Therapeutics Inc. statistics & valuation
Market cap$10.9B
P / B16.5×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | — | — | — | -10225.4% | -4764.3% |
| Net margin | — | — | — | -11174.8% | -4897.8% |
| FCF margin | — | — | — | -5986.7% | -4029.5% |
| Return on assets | -143.7% | -50.8% | -303.0% | -11.9% | -78.2% |
| Return on equity | -163.9% | -56.9% | -791.5% | -62.2% | -106.4% |
| Current ratio | 9.87 | 10.15 | 9.30 | 16.93 | 3.80 |
| Revenue growth | — | — | -100.0% | -61.0% | 110.3% |
Source: SEC EDGAR filings · CIK 0001599298 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.